REGENTIS BIOMATERIALS LTD

Their core work

Regentis Biomaterials is an Israeli medical device SME specializing in synthetic biomaterial implants for cartilage repair. Their flagship product, GelrinC, is a resorbable hydrogel-based scaffold designed to regenerate hyaline cartilage in the knee — a rare example of a company that has taken a biomaterial concept through to clinical-stage validation within the EU framework. Beyond their core implant business, they participate in research on advanced responsive biomaterials, including ultrasound-triggered materials and handheld bioprinting technologies for soft tissue engineering. Their H2020 work spans both commercial product development (Phase 2 SME Instrument) and early-stage collaborative research, making them an unusual hybrid of deep-tech startup and clinical-phase medtech company.

What they specialise in

How they've shifted over time

Both H2020 projects were active in the same window (2019–2023), so the keyword shift is not strictly temporal but reflects two parallel strategic tracks. The ADMAIORA track — ultrasound stimulation, remotely triggerable materials, handheld bioprinting, stem cells — represents an exploratory, research-oriented engagement with next-generation tissue engineering tools. The CHAMPION track — GelrinC, clinical study, implant, knee — represents their commercial core: a defined product in late-stage clinical validation. The direction this suggests is a company consolidating its proprietary implant technology while maintaining antenna in the broader biomaterials innovation space.

Regentis appears to be converging toward commercial medtech maturity — their most funded project is clinical validation of their own product, suggesting future collaborations will likely center on market access, regulatory pathways, and post-market studies rather than early-stage research.

How they like to work

Regentis has acted as both coordinator and participant, and notably chose to lead their highest-value project (CHAMPION, EUR 2.18M) themselves — a sign that they are capable of and willing to drive EU projects when their core IP is at stake. Their consortia are small (around 7 partners across two projects), which is consistent with a focused SME that prefers tight, specialist partnerships over broad networks. This suggests a partner who will engage actively and bring proprietary technology to the table, rather than serving as a passive participant.

Regentis has collaborated with 7 unique partners across 6 countries through their two projects, indicating a genuinely European (and Israeli) network despite being a small company. Their geographic spread is consistent with the international nature of clinical-stage medical device consortia.

What sets them apart

Regentis is unusual in the EU research landscape because they are a clinical-stage SME with a named, proprietary product (GelrinC) — not a research lab exploring a concept, but a company using EU funding to validate something they intend to sell. For consortium builders in orthopaedics, regenerative medicine, or biomaterials, this means Regentis brings both IP and clinical development experience, not just research capacity. They are one of the few Israeli SMEs active in EU biomaterials programs, which can add geographic and regulatory diversity to a consortium seeking EEA-adjacent clinical trial sites.

Highlights from their portfolio

• CHAMPION
  Regentis coordinated this EUR 2.18M SME Instrument Phase 2 grant to bring their own GelrinC cartilage implant through clinical study — the largest investment in their H2020 portfolio and a direct commercial development effort.
• ADMAIORA
  As a participant in this RIA project on ultrasound-responsive nanocomposites for osteoarthritis, Regentis contributed biomaterials expertise to a multi-partner research consortium, demonstrating breadth beyond their proprietary product.